Canakinumab

From WikiMD.org
Jump to navigation Jump to search

Canakinumab (pronunciation: /ˌkænəˈkɪnjuːmæb/) is a monoclonal antibody designed for the treatment of various autoinflammatory syndromes. It is a human monoclonal antibody targeted at interleukin-1 beta.

Etymology

The name "Canakinumab" comes from the words "canakin", an old term for a small can or drinking vessel, and "mab", an abbreviation for monoclonal antibody. The "canakin" part of the name is a reference to the drug's ability to "hold" or "contain" the inflammatory response, much like a vessel holds liquid.

Usage

Canakinumab is used for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including familial cold autoinflammatory syndrome and Muckle-Wells syndrome. It is also used in the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA), Adult-Onset Still's Disease (AOSD), and Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS).

Mechanism of Action

Canakinumab works by blocking the action of interleukin-1 beta. This protein is part of the body's immune response and is produced in excess in people with autoinflammatory syndromes. By blocking the action of interleukin-1 beta, canakinumab helps to reduce the symptoms of these conditions.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski